MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Operating Income 2011-2026 | VNRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -27 M | -36 M | -31.8 M | -28.3 M | -21.2 M | -16 M | -17.9 M | -14.7 M | -12.4 M | -10 M | -5.95 M | -4.58 M | -4.08 M | -2.61 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.61 M | -36 M | -16.6 M |
Quarterly Operating Income VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.1 M | -6.3 M | -5.52 M | - | -5.87 M | -6.99 M | -8.38 M | - | -8.65 M | -9.55 M | -9.05 M | - | -7.99 M | -8.1 M | -7.68 M | - | -7.56 M | -5.9 M | -6.09 M | - | -4.5 M | -5.21 M | -5.87 M | - | -4.18 M | -4.15 M | -3.99 M | - | -4.45 M | -4.57 M | -4.63 M | - | -3.88 M | -3.44 M | -3.34 M | - | -3.48 M | -2.98 M | -2.49 M | - | -2.97 M | -2.02 M | -2.35 M | - | -1.76 M | -1.05 M | -1.24 M | - | -926 K | -1.05 M | -908 K | - | -873 K | -931 K | -802 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -802 K | -9.55 M | -4.45 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.35 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 107.62 | -0.63 % | $ 4.25 B | USA |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 13.82 | -2.68 % | $ 418 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
|
Biodesix
BDSX
|
-34.5 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
912 M | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.36 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
-833 M | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 18.74 | -0.03 % | $ 999 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
-437 M | $ 93.21 | 1.06 % | $ 11.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
311 M | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 174.33 | 0.03 % | $ 30 B | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.2 | -2.09 % | $ 99.4 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Myriad Genetics
MYGN
|
-387 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Natera
NTRA
|
-541 M | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 10.93 | -1.97 % | $ 2.37 B | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |